Acalabrutinib

In this video, Jason Westin, MD, discusses the results of the Smart Stop trial, presented at ASH Annual Meeting and Exposition.

Time-limited dual B-cell receptor inhibitor therapy with acalabrutinib, umbralisib and ublituximab showed potential in treatment-naive and relapsed/refractory chronic lymphocytic leukemia, according to data presented at ASH Annual Meeting.

Healio spoke with Ryan. W. Jacobs, MD, about treatment options available to patients with CLL.

Healio spoke with Ryan. W. Jacobs, MD, about recent advancements in the management of CLL.

In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed the study he presented at ASCO21 that showed progression-free survival rates were equal among patients with CML treated with acalabrutinib vs. ibrutinib.

Acalabrutinib proved noninferior to ibrutinib in terms of PFS and resulted in less cardiotoxicity and fewer discontinuations due to adverse effects in a head-to-head trial among patients with previously treated chronic lymphocytic leukemia.

Acalabrutinib conferred a similar PFS benefit as ibrutinib for adults with previously treated high-risk chronic lymphocytic leukemia, according to topline results of a randomized phase 3 trial.

The increasing number of deaths in the United States due to COVID-19 has underscored the need to identify populations at elevated risk for virus-related mortality.

Acalabrutinib appeared effective and safe compared with standard regimens for relapsed or refractory chronic lymphocytic leukemia, according to long-term study results presented at Society of Hematologic Oncology Annual Meeting.

Since the COVID-19 pandemic began, researchers around the world have joined the effort to develop a vaccine and test potential treatments.